A 2143-g female infant was born at 38 weeks to a 19-year-old gravida 1, para 1 mother. The pregnancy was complicated by smoking, an unspecified viral illness 3 weeks prior to delivery with symptoms of vomiting and diarrhea, and decreased fetal movements 2 weeks prior to delivery. The decreased fetal movements persisted until birth. A follow-up ultrasound 4 weeks prior to delivery done for placenta previa was unremarkable. The mother's prenatal tests were within normal limits and she denied alcohol or illicit drug use. Family history was negative for bleeding disorders.
this time, the possibility of the hemorrhage being from a vein of Galen aneurysm was raised and the child was transferred to our institution. Initial physical exam was performed with findings consistent with previous one. However, the head circumference had increased by 1.5 cm. The neurological exam revealed absence of Moro reflex, sluggish pupillary reactions to light, with intact extraocular movements and brisk deep tendon reflexes. Another head CT was performed without contrast ( Figure 4 ) and showed the intraparenchymal and interventricular hemorrhage to be stable, with some decrease in hydrocephalus.
The CMV urine cultures and CMV-specific serum IgM were positive. A color Doppler ultrasound scan on the fifth day of life could not find an arteriovenous malformation. An ophthalmology exam was normal with no chorioretinitis. Audiometric testing was also 
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found to be normal. On day of life 13, a head ultrasound was repeated and revealed reduction in the size of the lateral ventricles and substantial improvement in the hemorrhage. The infant was discharged after 10 days when she was feeding well, the platelet count was stable, and there were no more seizures.
DISCUSSION
We believe that CMV-induced thrombocytopenia led to intracranial hemorrhage in this neonate, in view of the temporal relationship of the maternal viral illness (3 weeks before delivery), decreased fetal movement (2 weeks before delivery), forceps extraction, and a low infant platelet count at birth. The intracranial hemorrhage appears to be a perinatal event, but when the bleed actually occurred is difficult to define. CMV is the most common congenital infection with an incidence of approximately 1% of all newborns (range 0.2-2.4%). 1 Moreover, it is a leading infectious cause of mental retardation and nonhereditary sensorineural deafness. 2 CMV is a species-specific DNA virus and a member of the Herpesviridae family. The virus is spread through bodily secretions or tissues. Those at risk of infection include people in close nonsexual or sexual contact with a person shedding the virus, those receiving infected tissue transplants or blood products, and the fetuses of infected mothers. Vertical transmission of CMV to an infant occurs in utero by transplacental passage of maternal bloodborne virus, at birth through an infected maternal genital tract, or postnatally by ingestion of CMV-positive human milk. 3 Mothers who are infected early in pregnancy are more likely to give birth to infants who are small for gestational age and microcephalic with intracranial calcifications. When the mothers are infected later in pregnancy, their infants are more likely to manifest hepatitis, pneumonia, and thrombocytopenia. In this case, the infant's marked thrombocytopenia and mild hepatitis, and the maternal virus-like illness 3 weeks prior to delivery suggest maternal infection with CMV during late pregnancy.
A primary maternal infection is best documented by showing seroconversion of IgG antibodies to CMV during pregnancy, 4 but this was not documented in this case. Prenatal diagnosis of congenital CMV infection is most sensitive by PCR on amniotic fluid sampled after 21 weeks' gestation. 5 Recently, quantitative PCR of CMV DNA in amniotic fluid taken at 21-23 weeks' gestation of at least 10 genome equivalents/ml gave a 100% certainty of detecting an infected fetus. 6 In addition, a level of 10 5 genome equivalents/ml identified all the fetuses likely to have symptomatic infection and gave a 94% probability of excluding test-negative fetuses ( <10 5 genome equivalents/ml) from having a symptomatic infection. 6 In view of the current case report, it may be relevant to perform these tests during pregnancy if the fetal ultrasound shows IVH and/or ventriculomegaly.
The diagnosis of CMV in the newborn is most conclusively established by isolating the virus from urine, peripheral blood leukocytes, or other tissues and body fluids. Proof of congenital infection requires obtaining specimens within 3 weeks of birth, as in this case. After 3 weeks, the possibility of perinatal or postnatal infections is difficult to exclude. 2 In immunocompromised hosts, detection of pp65 antigen in white blood cells has proven to be useful in diagnosis. 3 From 90% to 95% of neonates with congenital CMV infection are asymptomatic in the neonatal period. 7 Central nervous system manifestations, which have been reported with congenital CMV infection, include lethargy, poor feeding, hyper-or hyptonia, microcephaly, intracranial calcifications, chorioretinitis, and sensorineural deafness. 2, 8 In this case, the serious sequelae of chorioretinitis and sensorineural deafness were not evident by physical exam and audiometric testing. The infant did have marked hypotonia and inactivity that had improved slowly by discharge and she was small for gestational age. On CT, there was no evidence of intracranial calcifications which are associated with a poor prognosis. 9 The two antiviral agents that are used for the treatment of severe, life-threatening, or sight-threatening disease in immunocompromised patients are ganciclovir and foscarnet. Ganciclovir is not routinely recommended in babies with congenital CMV because of insufficient efficacy data. 3 We are aware of just one previous report describing an association between congenital CMV infection and intracranial hemorrhage. 10 This relationship of CMV infection and intracranial hemorrhage has been reported in adults with only 10 cases as of 1998.
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Intraventricular hemorrhage occurs in 3.5% of term newborns. In approximately 25% of these affected term infants, there is no definable pathogenetic factors. 12 As CMV infects 40,000 newborns, it may be important to test for CMV in term infants with IVH with no definable cause. 
